Bayer : Blow to 'asundexian' (>€ 5bn in peak sales) as major part in phase III study was stopped early. Loss on glyphosate, $ 1.56bn to four plaintiffs
>Blow to 'asundexian' (>€ 5bn in peak sales) - OCEANIC-AF (phase III) study stopped early due to inferior efficacy - On Sunday, Bayer announced that OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk of stroke is being stopped early. This decision was based on the recommendation from the study’s Independent Data Monitoring Committee (IDMC) as part of ongoing surveillanc...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.